This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
| Sneeuwvlok Score | |
|---|---|
| Waardering | 4/6 |
| Toekomstige groei | 3/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 4/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
+ 1 meer risico
Kazia Therapeutics Limited Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | AU$0.08 |
| 52 Week Hoogtepunt | AU$0.24 |
| 52 Week Laag | AU$0.051 |
| Bèta | 2.13 |
| 11 maand verandering | -13.04% |
| 3 maanden verandering | -46.67% |
| 1 Jaar Verandering | -17.53% |
| 33 jaar verandering | -94.90% |
| 5 jaar verandering | -78.67% |
| Verandering sinds IPO | -97.65% |
Recent nieuws en updates
Recent updates
We're Not Worried About Kazia Therapeutics' (ASX:KZA) Cash Burn
Jun 24
We're Not Worried About Kazia Therapeutics' (ASX:KZA) Cash Burn
Feb 24We Take A Look At Why Kazia Therapeutics Limited's (ASX:KZA) CEO Compensation Is Well Earned
Nov 03We Think Kazia Therapeutics (ASX:KZA) Can Easily Afford To Drive Business Growth
Sep 23We Think Kazia Therapeutics (ASX:KZA) Can Afford To Drive Business Growth
May 04When Will Kazia Therapeutics Limited (ASX:KZA) Turn A Profit?
Mar 27Could The Kazia Therapeutics Limited (ASX:KZA) Ownership Structure Tell Us Something Useful?
Feb 28What Can We Learn About Kazia Therapeutics' (ASX:KZA) CEO Compensation?
Feb 01
We Think Kazia Therapeutics (ASX:KZA) Can Afford To Drive Business Growth
Jan 06Bullish: Analysts Just Made An Incredible Upgrade To Their Kazia Therapeutics Limited (ASX:KZA) Forecasts
Dec 11Kazia Therapeutics Limited (ASX:KZA): When Will It Breakeven?
Nov 26Rendement voor aandeelhouders
| KZA | AU Biotechs | AU Markt | |
|---|---|---|---|
| 7D | -27.3% | 1.5% | -0.7% |
| 1Y | -17.5% | 18.3% | 17.1% |
Rendement versus industrie: KZA underperformed the Australian Biotechs industry which returned -11.1% over the past year.
Rendement versus markt: KZA underperformed the Australian Market which returned -0.5% over the past year.
Prijsvolatiliteit
| KZA volatility | |
|---|---|
| KZA Average Weekly Movement | 22.9% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in AU Market | 17.5% |
| 10% least volatile stocks in AU Market | 3.6% |
Stabiele aandelenkoers: KZA's share price has been volatile over the past 3 months.
Volatiliteit in de loop van de tijd: KZA's weekly volatility has increased from 16% to 23% over the past year.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1994 | n/a | John Friend | www.kaziatherapeutics.com |
Kazia Therapeutics Limited Samenvatting
| KZA fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | AU$18.91m |
| Inkomsten(TTM) | -AU$20.47m |
| Inkomsten(TTM) | AU$555.00 |
Over9,999x
P/S-verhouding-0.9x
Koers/WinstverhoudingIs KZA overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| KZA resultatenrekening (TTM) | |
|---|---|
| Inkomsten | AU$555.00 |
| Kosten van inkomsten | AU$0 |
| Brutowinst | AU$555.00 |
| Overige uitgaven | AU$20.47m |
| Inkomsten | -AU$20.47m |
Laatst gerapporteerde inkomsten
Jun 30, 2023
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -0.087 |
| Brutomarge | 100.00% |
| Nettowinstmarge | -3,687,419.82% |
| Schuld/Eigen Vermogen Verhouding | 14.9% |
Hoe presteerde KZA op de lange termijn?
Bekijk historische prestaties en vergelijking